Show simple item record

dc.contributor.authorSweeney, J.B.
dc.contributor.authorRattray, Marcus
dc.contributor.authorPugh, V.
dc.contributor.authorPowell, L.A.
dc.date.accessioned2018-09-17T16:17:44Z
dc.date.available2018-09-17T16:17:44Z
dc.date.issued2018-06-14
dc.identifier.citationSweeney JB, Rattray M, Pugh V and Powell LA (2018) Riluzole-Triazole Hybrids as Novel Chemical Probes for Neuroprotection in Amyotrophic Lateral Sclerosis. ACS Medicinal Chemistry Letters. 9(6): 552-556.en_US
dc.identifier.urihttp://hdl.handle.net/10454/16574
dc.descriptionyesen_US
dc.description.abstractDespite intense attention from biomedical and chemical researchers, there are few approved treatments for amyotrophic lateral sclerosis (ALS), with only riluzole (Rilutek) and edaravone (Radicava) currently available to patients. Moreover, the mechanistic basis of the activity of these drugs is currently not well-defined, limiting the ability to design new medicines for ALS. This Letter describes the synthesis of triazole-containing riluzole analogues, and their testing in a novel neuroprotective assay. Seven compounds were identified as having neuroprotective activity, with two compounds having similar activity to riluzole.en_US
dc.language.isoenen_US
dc.relation.isreferencedbyhttps://doi.org/10.1021/acsmedchemlett.8b00103en_US
dc.rights© 2018 ACS. This document is the Accepted Manuscript version of a Published Work that appeared in final form in ACS Medicinal Chemistry Letters, copyright © American Chemical Society after peer review and technical editing by the publisher. To access the final edited and published work see https://doi.org/10.1021/acsmedchemlett.8b00103en_US
dc.subjectMotor neuron diseaseen_US
dc.subjectPrimary cortical neuronsen_US
dc.subjectRiluzoleen_US
dc.subjectAmyotrophic lateral sclerosis (ALS)en_US
dc.subjectTriazolesen_US
dc.subjectNeuroprotective activityen_US
dc.titleRiluzole–Triazole Hybrids as Novel Chemical Probes for Neuroprotection in Amyotrophic Lateral Sclerosisen_US
dc.status.refereedn/aen_US
dc.date.Accepted2018-05-30
dc.typeLetteren_US
dc.type.versionAccepted Manuscripten_US
dc.description.publicnotesThe full text will be available at the end of the publisher's embargo, 14th June 2019.en_US


Item file(s)

Thumbnail
Name:
Authors text.pdf
Embargo:
2019-06-14
Size:
315.5Kb
Format:
PDF
Description:
Main article
Thumbnail
Name:
Supporting information.pdf
Embargo:
2019-06-14
Size:
2.828Mb
Format:
PDF
Description:
Supporting information

This item appears in the following Collection(s)

Show simple item record